FDA Guides On Rivals To Primatene Mist And Spiriva Respimat
Agency Releases Batch Of 34 Product-Specific Guidances
A batch of almost three dozen new and revised product-specific guidances for generic products has been published by the US Food and Drug Administration, including for rivals to Primatene Mist (epinephrine) metered-dose inhaler and Spiriva Respimat (tiotropium bromide) inhalation spray.
You may also be interested in...
Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”